Qiagen NV

QGEN

50.3150.46% ( -0.235 )

Trading: Nov 10, 14:49:20 (EDT)

Open: 50.480
High: 50.550
Low: 50.200
Prev. Close: 50.550
Volume: 3.08M
Turnover: 154.89M
Avg Price: 50.347
Bid/Ask Ratio: -50.68%
Amplitude: 0.69%
52wk High: 57.298
Volume Ratio: 1.76
Turnover Ratio: 1.50%

52wk Low: 32.239
Float Mkt Cap: 10.32B
Market Cap^USD: 10.39B
P/E^TTM: 26.99
P/E^Dynamic: 24.58
P/E^Static: --
EPS^TTM: 1.86
EPS^Dynamic: 2.05
EPS^Static: --
BVPS: 16.83
P/B: 2.99
Circulating Supply: 205.13M
Dividend Yield^TTM: 0.70%
Dividend^TTM: 0.35
Shares: 206.50M
Min lot size: 1
Currency: USD

Qiagen NV Analyst Rating

Forecast & Rating

Nov 5, 2026

Price forecast

$49.59-1.44%

Forecast & RatingHold

12analysts

Strong buy0.00%
Buy8.33%
Hold91.67%
Sell0.00%
Strong sell0.00%

News

Posts

Bullish vs. Bearish — Last 3 Months

100 followers · 0 opinions

▲Bullish50%

50%Bearish▼

H
Hardik ShahMay 19, 2026 at 08:07 PM
📢 𝐉𝐔𝐒𝐓 𝐈𝐍: QIAGEN Partners With NVIDIA to Advance AI-Driven Drug Discovery - $Qiagen NV(QGEN.US) $NVIDIA(NVDA.US)
👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:
➤ QIAGEN collaborates with 𝐍𝐕𝐈𝐃𝐈𝐀 to integrate AI into bioinformatics workflows.
➤ Partnership combines QIAGEN biomedical databases with 𝐍𝐕𝐈𝐃𝐈𝐀 𝐁𝐢𝐨𝐍𝐞𝐌𝐨 platform.
➤ Focus on identifying 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 𝐦𝐞𝐜𝐡𝐚𝐧𝐢𝐬𝐦𝐬, biomarkers, and therapeutic targets.
➤ Integration applies 𝐠𝐫𝐚𝐩𝐡-𝐛𝐚𝐬𝐞𝐝 𝐀𝐈 to complex biological datasets.
➤ Supports drug discovery use cases including 𝐝𝐫𝐮𝐠 𝐫𝐞𝐩𝐮𝐫𝐩𝐨𝐬𝐢𝐧𝐠 and pathway analysis.
➤ QIAGEN knowledge bases currently serve 𝟏𝟓𝟎,𝟎𝟎𝟎+ scientists globally.
➤ Initial pilot programs launching with select 𝐩𝐡𝐚𝐫𝐦𝐚 and biotech partners.